Skip to main content

Table 3 Adverse events

From: Use of antipsychotics and benzodiazepines in patients with psychiatric emergencies: Results of an observational trial

Event, MedDRA preferred term All patients Olanzapine Non-Olanzapine Risperidone Non-Risperidone Haloperidol Non-Haloperidol
  (N = 558) (N = 390) (M = 168) (N = 72) (N = 486) (N = 132) (N = 426)
Treatment-emergent adverse events, n (%) 37 (6.6) 24 (6.2) 13 (7.7) 8 (11.1) 29 (6.0) 13 (9.8) 24 (5.6)
   Dyskinesiaa, n (%) 4a (0.7) 2 (0.5) 2 (1.2) 0 (0.0) 4 (0.8) 3 (2.3) 1 (0.2)
   Extrapyramidal disorder, n (%) 4 (0.7) 1 (0.3) 3 (1.8) 1 (1.4) 3 (0.6) 2 (1.5) 2 (0.5)
   Sedation, n (%) 4 (0.7) 3 (0.8) 1 (0.6) 1 (1.4) 3 (0.6) 2 (1.5) 2 (0.5)
   Dizziness postural, n (%) 3 (0.5) 3 (0.8) 0 (0.0) 0 (0.0) 3 (0.6) 2 (1.5) 1 (0.2)
   Weight increased, n (%) 3 (0.5) 3 (0.8) 0 (0.0) 1 (1.4) 2 (0.4) 0 (0.0) 3 (0.7)
   Akathisia, n (%) 2 (0.4) 2 (0.5) 0 (0.0) 1 (1.4) 1 (0.2) 0 (0.0) 2 (0.5)
   Oculogyric crisis, n (%) 2 (0.4) 2 (0.5) 0 (0.0) 1 (1.4) 1 (0.2) 0 (0.0) 2 (0.5)
   Salivary hypersecretion, n (%) 2 (0.4) 1 (0.3) 1 (0.6) 1 (1.4) 1 (0.2) 0 (0.0) 2 (0.5)
Adverse events considered related to primary AP medication, n (%) 33 (5.9) 21 (5.4) 12 (7.1) 8 (11.1) 25 (5.1) 12 (9.1) 21 (4.9)
Serious adverse events, n (%) 4 (0.7) 2 (0.5) 2 (1.2) 0 (0.0) 4 (0.8) 3 (2.3) 1 (0.2)
Serious adverse events considered related to primary AP medication, n (%) 2 (0.4) 1 (0.3) 1 (0.6) 0 (0.0) 2 (0.4) 2 (1.5) 0 (0.0)
Clinically significant adverse events resulting in discontinuation, n (%) 2 (0.4) 1 (0.3) 1 (0.6) 1 (1.4) 1 (0.2) 0 (0.0) 2 (0.5)
  1. Only preferred terms occurring in at least 2 patients are listed.
  2. Patients may be included in more than one category of event or preferred term.
  3. a Includes the following original terms as reported by physicians: early dyskinesias (n = 3), perioral dyskinesia (n = 1).